Today: 29 June 2026
Browse Category

NASDAQ:JAZZ 25 August 2025 - 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® in a large global trial for HER2‑positive gastroesophageal adenocarcinoma. The news has triggered sharp pre‑market moves in Jazz’s share price and its partners’ stocks, and could reshape the treatment landscape for a difficult‑to‑treat cancer. PR Newswire+1 As of early afternoon U.S. trading on Monday, November 17, Jazz Pharmaceuticals shares are trading around $141.07, little changed on the day according to real‑time quote data.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal adenocarcinoma, a group that includes cancers of the stomach, gastroesophageal junction, and esophagus. GlobeNewswire+1 The trial compared three regimens:
17 November 2025
····
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have approved the merger, which is expected to close in Q1 2026 pending regulatory and shareholder approval. The takeover news sent AVDL shares sharply higher. After opening Oct. 22 at about $17.87, the stock gained further in early trading. Avadel topped ~$18.40 intraday, well above its 200-day moving average marketbeat.com. As one observer noted, the stock “crossed above its 200-day moving average of $11.36” and traded at multi-month highs marketbeat.com. Overall, trading volume on Oct. 22 surged to roughly 6.8 million shares, indicating heavy investor interest.
22 October 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com. “Making America Healthy Again” or Undermining Science?: The narrower vaccine rollout comes amid turmoil at the CDC. CDC Director Dr. Susan Monarez was fired on Aug. 27, just weeks into the job, after clashing with HHS Secretary Robert F. Kennedy Jr. over his sweeping vaccine policy changes reuters.com reuters.com. Kennedy –
28 August 2025
····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

This comprehensive roundup highlights the fast-moving developments in biotech, pharma, and health over the past 48 hours. From life-saving drugs and high-stakes deals to public health challenges, the landscape is evolving daily. As always, readers are advised to consult original sources and official health guidance for more details. Sources: Key information has been drawn from Reuters, AP News, FDA/CDC releases, and expert commentary to ensure accuracy and timeliness reuters.com reuters.com reuters.com thewellnews.com reuters.com reuters.com, among other cited references throughout this report.
25 August 2025
······

Stock Market Today

  • Kimco Realty (KIM.PRL) Sets Quarterly Preferred Dividend; Ex-Date July 1
    June 29, 2026, 3:11 PM EDT. Kimco Realty Corp's Class L Preferred Stock (KIM.PRL) goes ex-dividend July 1, 2026, with $0.3203 per share due July 15. At Friday's close of $19.33, the annualized yield is about 6.63%. On the ex-date, shares are set to drop by about 1.66%. That payout is lower than the 8.12% average for preferreds in Real Estate. Monday, KIM.PRL eked out a 0.1% gain, while Kimco common (KIM) was unchanged. Kimco makes up 3.28% of the Invesco S&P 500 Equal Weight Real Estate ETF (RSPR). Preferred stocks such as KIM.PRL appeal to investors looking for steady real estate income.
Go toTop